Disclaimer: The views expressed are those of the authors and do not necessarily represent the official position of the U.S. Food and Drug Administration.
1096-8652/asset/olbannerleft.gif?v=1&s=d9288d4b31f0b8e9a1eb2d195cb165e0aa1d7a97)
1096-8652/asset/olbannerright.gif?v=1&s=78488ac502104a3d829e729353def6ce62dc1e29)
Research Article
You have full text access to this OnlineOpen article
Use of parenteral iron products and serious anaphylactic-type reactions†‡§
Article first published online: 15 JUN 2010
DOI: 10.1002/ajh.21794
Published 2010 Wiley-Liss, Inc.
Additional Information
How to Cite
Wysowski, D. K., Swartz, L., Vicky Borders-Hemphill, B., Goulding, M. R. and Dormitzer, C. (2010), Use of parenteral iron products and serious anaphylactic-type reactions. Am. J. Hematol., 85: 650–654. doi: 10.1002/ajh.21794
- †
- ‡
Conflict of interest: Nothing to report.
- §
This article is a US Government work and, as such, is in the public domain in the United States of America.
Publication History
- Issue published online: 25 AUG 2010
- Article first published online: 15 JUN 2010
- Manuscript Accepted: 9 JUN 2010
- Manuscript Revised: 8 JUN 2010
- Manuscript Received: 14 JAN 2010
References
- 1. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004; 15: S93-S98.
- 2,,,. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004; 19: 1571–1575.
- 3,,,. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378–382.
- 4,,, et al. High-molecular weight iron dextran: A wolf in sheep's clothing? J Am Soc Nephrol 2008; 19: 833–834.
- 5IMS Health, National Sales Perspective.™ Combined data from retail and non-retail, 2002-2007. IMS Health, Plymouth Meeting, Pa. Data extracted 3/29/07 and 7/7/08.
- 6,. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. Arch Intern Med 2005; 165: 1363–1369.
- 7Public use data tape documentation. Multiple cause of death for ICD-9 and ICD-10 data. Hyattsville, MD: U.S. Department of Health and Human Services, Public Health Service, National Center for Health Statistics.
- 8Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death, 9th revision. Geneva, Switzerland: World Health Organization, 1977.
- 9International Statistical Classification of Diseases and Related Health Problems, 10th revision. Geneva, Switzerland: World Health Organization, 1992.
- 10,. Analyzing prescription drugs as causes of death on death certificates (letter). Public Health Rep 2004; 119: 520.
- 11,,, et al. Evaluation and overview of the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project (NEISS-CADES). Med Care 2007; 45: S96–S102.
- 12Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2003: Interim National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-26. DHHS Publication No. (SMA) 04-3972. Rockville, MD, 2004.
- 13Facts and Comparisons Online 2010 by Wolters Kluwer Health, Inc. Accessed 3-11-10.
- 14,,. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran—A comparison of two products. Am J Nephrol 2000; 20: 456–462.
- 15,,,. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001; 37: 743–749.
- 16,. Benchmarking iron dextran sensitivity: Reactions requiring resuscitative medication in incident and prevalent patients. Nephrol Dial Transplant 2005; 20: 1438–1442.
- 17,,, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28: 529–534.
- 18,,. Parenteral iron therapy: A single institution's experience over a 5-year period. J Natl Comprehensive Cancer Network 2005; 3: 791–795.
- 19,,, et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003; 63: 217–224.
- 20,,, et al. The comparative safety of various intravenous iron preparations. Renal Failure 2008; 30: 629–638.
- 21,. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextran. Am J Kidney Dis 1999; 33: 464–470.
- 22,,,. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005; 20: 1443–1449.
- 23,,, et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 2002; 61: 1830–1839.
- 24. The safety of sodium ferric gluconate complex in haemodialysis patients has been extensively evaluated. Nephrol Dial Transplant 2005; 20: 1770.
- 25,,, et al. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs. iron gluconate (Ferrlecit) in hemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001; 16: 1239–1244.
- 26,,, et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 2001; 37: 300–307.
- 27,,, et al. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis 1999; 33: 471–482.
- 28,. Parenteral iron therapy options. Am J Hematol 2004; 76: 74–78.Direct Link:
- 29,,, et al. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 34: 286–290.
- 30,,, et al. Rapid (sixty minutes) infusion of one gram of low molecular iron dextran: Safety and efficacy profile. Blood (ASH annual meeting Abstracts) 2009; 114:abstract 4054.
- 31,. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 2006; 1: S19–S23.